Does Ingrezza Cause Weight Gain?
Ingrezza (valbenazine), used to treat tardive dyskinesia, lists weight gain as a possible side effect in clinical data, but it occurs infrequently. In pivotal trials, about 3-5% of patients reported weight increased versus 2% on placebo.[1][2] Post-marketing reports note rare cases of significant gain, though not established as causal.[3]
How Common Is Weight Gain on Ingrezza?
Clinical studies (e.g., KINECT trials) show low incidence: 2.2% in long-term extension (up to 48 weeks) at 40-80 mg doses, similar to placebo rates.[1] Real-world data from patient registries and FDA adverse event reports indicate it's not among top side effects like somnolence (10-20%) or fatigue.[2][4] Factors like dosage, duration, or concurrent antipsychotics (common in TD patients) may contribute more than Ingrezza alone.
What Do Patients Report About Weight Changes?
User reviews on platforms like Drugs.com average 5.5/10, with some noting 5-15 lb gain over months, often tied to appetite increase or sedentary effects from sedation.[5] Others report no change or loss. FDA's FAERS database logs ~200 weight gain cases since 2017 approval, but underreporting is common and causality unproven.[4]
Why Might Ingrezza Affect Weight?
As a VMAT2 inhibitor, it modulates dopamine without direct metabolic impact, unlike some antipsychotics causing gain via histamine or serotonin blockade. Any effect likely stems from indirect sedation reducing activity or mild appetite shifts, not core mechanism.[3][6] No black-box warnings for metabolic changes.
Compared to Other Tardive Dyskinesia Treatments
| Treatment | Weight Gain Risk | Notes |
|-----------|------------------|-------|
| Ingrezza (valbenazine) | Low (2-5%) | Minimal metabolic disruption [1] |
| Austedo (deutetrabenazine) | Low (1-3%) | Similar profile; head-to-head trials show equivalence [7] |
| Typical antipsychotics (e.g., haloperidol) | High (10-30%) | Often cause TD and gain [6] |
| Atypical antipsychotics (e.g., olanzapine) | Very high (20-40%) | Strong H1 antagonism [6] |
Patients switching from antipsychotics may see weight stabilize or drop on Ingrezza.[7]
What If You're Worried About Weight Gain?
Monitor BMI monthly; lifestyle adjustments (diet, exercise) mitigate rare cases. No dose adjustments needed solely for weight, per label. Consult prescriber if gain exceeds 5-10% body weight, as it could signal unrelated issues like hypothyroidism in TD patients.[3] No evidence of reversal issues post-discontinuation.
Sources
[1]: Ingrezza Prescribing Information (Neurocrine Biosciences)
[2]: FDA Label for Valbenazine
[3]: Drugs.com - Ingrezza Side Effects
[4]: FDA FAERS Public Dashboard
[5]: Drugs.com User Reviews
[6]: PubMed - VMAT2 Inhibitors Review
[7]: KINECT-HD Study (Neurocrine)